Urogen Pharma Ltd (URGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 109,788 | 90,398 | 82,713 | 64,357 | 48,042 |
| Cost of Goods | 12,447 | 8,881 | 9,361 | 7,654 | 5,157 |
| Gross Profit | 97,341 | 81,517 | 73,352 | 56,703 | 42,885 |
| Operating Expenses | 222,651 | 179,180 | 139,249 | 136,398 | 135,334 |
| Operating Income | -124,863 | -96,782 | -65,536 | -79,041 | -92,292 |
| Interest Expense | 15,345 | 12,521 | 14,715 | 8,438 | 0 |
| Other Income | -13,208 | -14,739 | -18,073 | -20,549 | -17,079 |
| Pre-tax Income | -153,416 | -124,042 | -98,324 | -108,028 | -109,371 |
| Income Tax | 78 | 2,832 | 3,920 | 1,755 | 1,449 |
| Net Income Continuous | -153,494 | -126,874 | -102,244 | -109,783 | -110,820 |
| Net Income | $-153,494 | $-126,874 | $-102,244 | $-109,783 | $-110,820 |
| EPS Basic Total Ops | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
| EPS Basic Continuous Ops | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
| EPS Diluted Total Ops | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
| EPS Diluted Continuous Ops | -3.19 | -2.96 | -3.55 | -4.81 | -4.96 |
| EPS Diluted Before Non-Recurring Items | N/A | -2.96 | -3.55 | -4.79 | -4.96 |
| EBITDA(a) | $-126,431 | $-99,344 | $-65,768 | $-78,615 | $-90,985 |